Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15079749 | 0.88 | MAPT (0.44) | KMT2AMAPTMEN1TSHRALDH1A1 | |
| SCHEMBL15079364 | 0.86 | MEN1 (0.47) | KMT2AMAPTMEN1TSHRALDH1A1 | |
| SCHEMBL15079914 | 0.82 | TSHR (0.46) | KMT2AMAPTMEN1TSHRALDH1A1 | |
| SCHEMBL15079755 | 0.79 | KMT2A (0.49) | KMT2AMAPTMEN1TSHRALDH1A1 | |
| SCHEMBL15079894 | 0.79 | SCN4A (0.47) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL15079881 | 0.79 | LTA4H (0.49) | MAPTADRB2LMNAADRB1ADRB3 | |
| SCHEMBL9854787 | 0.79 | CYP1A2 (0.41) | KMT2AMAPTMEN1TSHRLMNA | |
| SCHEMBL15079883 | 0.79 | KDM1A (0.46) | KMT2AMAPTMEN1ALDH1A1LMNA | |
| SCHEMBL15079844 | 0.78 | HTT (0.46) | KMT2AMAPTMEN1TSHRALDH1A1 | |
| SCHEMBL15079874 | 0.78 | RECQL (0.41) | KMT2AMAPTTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| WO-2013093320-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | ARG1, TYR, NOS1 | HTR7 1241/4885KMT2A 1478/4885MAPT 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.